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Objectives: Treatment switching adjustment methods are often used to adjust for switching in 
oncology randomized controlled trials (RCTs). In this exploratory analysis, we apply these 
methods to adjust for treatment changes in the setting of an RCT followed by an extension study 
in relapsing-remitting multiple sclerosis. 
Methods: The CLARITY trial evaluated cladribine tablets versus placebo over 96 weeks. In the 
96-week CLARITY Extension, patients who received placebo in CLARITY received cladribine 
tablets; patients who received cladribine tablets in CLARITY were re-randomized to placebo or 
cladribine tablets. Endpoints were time to first qualifying relapse (FQR) and time to 3- and 6-
month confirmed disability progression (3mCDP, 6mCDP). We aimed to compare the 
effectiveness of cladribine tablets to placebo over CLARITY and the extension. The rank 
preserving structural failure time model (RPSFTM) and Iterative Parameter Estimation (IPE) 
were used to estimate what would have happened if patients had received placebo in CLARITY 
and the extension, versus patients that received cladribine tablets and switched to placebo. To 
gauge whether treatment effect waned after the 96 weeks of CLARITY, we compared hazard 
ratios (HRs) from the adjustment analysis with HRs from CLARITY. 
Results: The RPSFTM resulted in a HR of 0.48 (95% confidence interval [CI] 0.36-0.62) for 
FQR, 0.62 (95% CI 0.46-0.84) for 3mCDP, and 0.62 (95% CI 0.44-0.88) for 6mCDP. IPE 
algorithm results were similar. CLARITY HRs were 0.44 (95% CI 0.34-0.58), 0.60 (95% CI 
0.41-0.87) and 0.58 (95% CI 0.40-0.83) for FQR, 3mCDP and 6mCDP respectively. 
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Conclusions: Treatment switching adjustment methods are applicable in non-oncology settings. 
Adjusted CLARITY plus CLARITY Extension HRs were similar to the CLARITY HRs, 
demonstrating significant treatment benefits associated with cladribine tablets versus placebo. 
Keywords: multiple sclerosis, treatment switching, rank-preserving structural failure time 
model, iterative parameter estimation, adjustment methods, time-to-event 
Key Points 
This article reports on an exploratory analysis, where the authors apply treatment switching 
adjustment methods to adjust for treatment changes in the setting of a randomized controlled trial 
(CLARITY) followed by an extension study (CLARITY Extension) in relapsing-remitting 
multiple sclerosis. This analysis demonstrates that treatment switching adjustment methods are 
applicable in non-oncology settings, and when trial designs are non-typical - i.e. in the context of 
extension studies, where it is common for patients randomized to placebo in the initial trial to all 
switch onto the experimental treatment in the extension study for ethical reasons. Use of 
adjustment methods in this setting provides decision makers with longer-term evidence for 




Treatment switching adjustment methods are often used to adjust for situations in oncology 
randomized controlled trials (RCTs) in which patients are permitted to switch from the control 
treatment to the intervention treatment after disease progression.[1-4] Results of these treatment 
switching adjustment analyses have been included as supporting evidence in a number of 
international health technology appraisals (HTAs) of cancer treatments.[5] However, these 
methods have rarely been applied outside of oncology.  
The National Institute for Health and Care Excellence Decision Support Unit Technical Support 
Document 16 describes four commonly used methods for adjusting for treatment switching in 
RCTs.[4] These are the rank-preserving structural failure time model (RPSFTM),[6] the iterative 
parameter estimation (IPE) algorithm,[7] inverse probability of censoring weights (IPCW),[8] 
and a two-stage accelerated failure time adjustment method.[9] In the strictest sense, the IPE is a 
type of RPSFTM, although here we specify IPE to distinguish thi  method from the standard 
RPSFTM.  
These methods for adjusting for treatment switching were examined using data from an RCT and 
extension study focused on assessing the efficacy of cladribine tablets (MAVENCLAD®, Merck 
KGaA), which are used to treat relapsing multiple sclerosis (MS). Relapsing–remitting MS is a 
chronic autoimmune neurodegenerative disease that progresses over a long period of time.[10] 
Management of the condition often involves the use of disease modifying treatments (DMT ), 
which can favorably change the course of the disease.[11] Many approved DMTs are 
administered parenterally, or through self-injection, whereas cladribine tablets represent one of 
the newer orally administered DMT options. 
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In this analysis, we apply treatment switching adjustment methods to an RCT followed by an 
extension study with re-randomization, in the context of MS. Extension trials involving treatment 
switching are common in MS due to ethical reasons; hence, these methods are applicable beyond 
this case-study. Our aim is to overcome the limitation in the data that patients in the placebo 
group of the trial switch onto an active treatment in the extension study, because this limits the 
assessment of long-term effectiveness of treatment compared with placebo using standard 
methods.  To correct for this, we apply treatment switching adjustment methods to estimate the 
long term effectiveness of an active MS treatment compared to a counterfactual placebo arm 





2.1.Trial design  
The Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY, ClinicalTrials.gov: 
NCT00213135) trial compared low-dose cladribine tablets (3.5 mg/kg; now the approved dose), 
high-dose cladribine tablets (5.25 mg/kg), and placebo over a 96-week period.[12] Each 
treatment course of cladribine tablets consisted of two treatment weeks per 48 week period, 
administered during the beginning of the first month and the beginning of the second month of 
the respective treatment year. 1326 patients were randomized 1:1:1 to compare three lines of 
treatment during the 96 weeks of the study. 437 patients received a placebo treatment, 433 
patients received low-dose cladribine tablets and 437 patients received high-dose cladribine 
tablets.[12] A full description of the CLARITY study methodology, including patient inclusion 
and exclusion criteria, has been published elsewhere.[12]  
After completion of CLARITY, participants were permitted to enter into a 96-week extension 
study, in which former placebo patients were assigned to treatment with low-dose cladribine and 
former low-dose cladribine patients were randomized 2:1 to receive further treatment with low-
dose cladribine tablets or placebo. Former high-dose patients were also included in the extension 
study, but the focus of this paper is on low-dose cladribine tablets, representing the dose 
approved by regulators.[13] 
The CLARITY Extension study was not pre-specified at the initiation of CLARITY and 
enrollment to the extension study did not begin immediately as the first patients in CLARITY 
completed the core study. The median per-patient time between the end of CLARITY and start 
of CLARITY Extension was 40.3 weeks. 806 of the patients in the CLARITY study enrolled in 
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the CLARITY Extension. Figure 1 indicates the treatment pathways for patients randomized to 
receive placebo or low-dose cladribine tablets in CLARITY. 
CLARITY and the CLARITY Extension were conducted in accordance with the Declaration of 
Helsinki (1964) and its later amendments [14] and the Good Clinical Practice guidelines in 
accordance with the International Conference of Harmonisation.[15] The protocols for 
CLARITY and CLARITY Extension were reviewed and approved by the relevant local review 
board or ethics committee at each participating study center. Further information has been 
published previously elsewhere. [12]  Due to ethical considerations, patients who received 
placebo in CLARITY received low-dose cladribine tablets in the extension; thus, no group 
received placebo in both CLARITY and CLARITY Extension. Of the 437 patients randomized 
to receive placebo in CLARITY, 171 patients did not enroll in the CLARITY Extension, and 22 
enrolled in the extension but did not receive treatment. The remaining 244 placebo group 
patients that enrolled into the extension trial received low-dose cladribine tablets. Of the 433 
patients that received low-dose cladribine in CLARITY, 132 did not enroll in the CLARITY 
Extension. 284 of the CLARITY low-dose group patients that enrolled in the extension study 
were re-randomized to receive either low-dose cladribine tablets (186 patients) or placebo (98 
patients). The remaining 17 low-dose cladribine patients enrolled in the extension for follow-up 
but were not randomized to receive treatment.  
As cladribine tablets demonstrated sustained long-term effects (see section 5.1 of the Summary 
of Product Characteristics[13]), patients who received placebo (PP) after low-dose cladribine 
tablets (LL) still benefited from initial treatment with cladribine during placebo treatment in the 
extension phase. Our aim was to assess the efficacy of a low-dose cladribine, low-dose 
cladribine, placebo, placebo treatment arm (denoted LLPP), compared to a placebo, placebo, 
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placebo, placebo arm (denoted PPPP), with each treatment block lasting 48 weeks. Note that the 
first two 48-week blocks were in CLARITY and the second two occurred in CLARITY 
Extension, after the bridging interval between studies. The intention was that all patients treated 
with placebo during CLARITY trial switched onto cladribine tablets in the extension study for 
ethical reasons, and therefore the PPPP treatment strategy was unobserved. Therefore, we used 
treatment switching adjustment methods to estimate the hypothetical outcome of the CLARITY 
placebo arm if patients had remained on placebo during the extension study and had not switched 
onto low-dose cladribine tablet treatment. We sought to compare LLPP to PPPP for the 
outcomes of 3-month disability progression (3mCDP), 6-month disability progression (6mCDP) 
and first qualifying relapse (FQR). 
2.2.Treatment switching adjustment methods 
Among the four commonly used methods for adjusting for treatment switching in RCTs, the 
IPCW and the two-stage method both require a proportion of non-switchers to be present in the 
arm that is to be adjusted.[4, 9, 8] Following CLARITY, all placebo group patients who enrolled 
in the extension switched onto low-dose cladribine tablets. For this reason, we could not adjust 
for treatment switching using the IPCW or the two-stage method. However, we could apply the 
RPSFTM and IPE methods because these do not require there to be non-switchers in the 
estimation process, provided that the mean treatment duration differs between patients in the 
initially randomized groups. As these methods have been described in detail elsewhere,[2, 4] 
here we describe only their key characteristics. 
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2.2.1. Application of the RPSFTM and IPE 
The applications of the RPSFTM and IPE involve two main steps. First, the value of the 
treatment effect, ね, is estimated. Typically, the RPSFTM and IPE use the randomization of the 
trial to estimate counterfactual event times, i.e., event times that would have been observed if no 
treatment had been received.[6] It is assumed that if no treatment was received by patients in 
either arm of the trial, the event times for each arm would be, on average, qual. Counterfactual 
event times for each patient can be estimated as follows:  
(time to event)i = (time off treatment)i + exp(ね) 抜 (time on treatment)i 
where ね represents the treatment effect, and i represents patient i. 
Hence, the value for the treatment effect ね can be identified at the point where the counterfactual 
event times are balanced in each arm. For the RPSFTM, this is achieved when the value of the 
log-rank Z test comparing counterfactual event times between arms is equal to zero.[6, 16] For 
the IPE, the treatment effect is determined at the point where the algorithm has converged.[7] 
The standard RPSFTM uses g-estimation to estimate the value of the treatment effect; this 
essentially consists of a grid search of possible values for ね until one is found that results in 
equal counterfactual event times across treatment arms.[6] In contrast, the IPE uses an iterative 
parametric testing procedure to estimate the value of the treatment effect.[7] In both cases, the 
treatment effect is estimated in the form of an acceleration factor (AF), where AF=exp(-ね). 
Second, counterfactual survival times in the group(s) in which switching occurred are compared 
to observed survival times in the group(s) in which switching did not occur, to obtain adjusted 
estimates of the treatment effect.  
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2.2.2. RPSFTM and IPE assumptions 
The RPSFTM and IPE rely on two key assumptions: the randomization assumption and the 
common treatment effect assumption.[7, 6] The randomization assumption assumes that, in the 
absence of treatment, outcomes would be equal in the randomized groups. This is likely to be 
reasonable in the context of an RCT. The common treatment effect assumption assumes that the 
effect of treatment is the same regardless of when it is received, relative to the amount of time 
for which it is taken. If the treatment effect received by switchers differs from that received by 
patients at initial treatment randomization, the RPSFTM and IPE will produce biased results. 
This assumption may be more problematic if patients who receive treatment later in the trial are 
considered to have a lower capacity to benefit from it. 
We applied the RPSFTM and IPE methods to the CLARITY plus CLARITY Extension context 
by combining the study periods and using a treatment switch indicator to represent the time when 
low-dose cladribine was started in patients who were initially randomized to placebo. In these 
analyses, we assumed the treatment benefit could be maintained after treatment had been 
discontinued; therefore, the treatment indicator remained set to “1” (i.e., “on” treatment) for all 
time periods after treatment was initiated. Patients who followed the LLPP treatment arm were 
modelled to remain “on treatment” during both periods because the impact of the treatment may 
still affect prognosis after treatment has been discontinued, and patients who followed the a 
placebo, placebo, low-dose cladribine, low-dose cladribine treatment arm (PPLL) treatment arm 
were modelled as being “off treatment” during the CLARITY period and “on treatment” during 
the extension period of the trial. Applying the methods in this way allows for the fact that 
sustained benefit has been observed after cladribine treatment has been discontinued, [15] and 
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also ensures that mean treatment durations will differ in the initially randomized groups – a 
requirement for RPSFTM and IPE models to be applicable. 
After counterfactual event times were obtained for switchers, hazard ratios (HRs) were 
estimated, using Cox proportional hazards regression models, for time from randomization to 
event (e.g., relapse or disability progression) for the LLPP arm compared with the counterfactual 
PPPP arm. For the RPSFTM, confidence intervals (CIs) were estimated for the adjusted HRs 
using a test-based procedure that retaind the p-value from the unadjusted intention to treat (ITT) 
analysis of the combined CLARITY plus CLARITY Extension datasets (for the comparison of 
LLPP and PPLL).[16] For the IPE estimates, we performed 1000 bootstrapped iterations of the 
adjustment procedure to estimate CIs around the adjusted HR. 
2.2.3. Selecting the preferred application 
Although they use different processes to obtain a value of ね, the RPSFTM and IPE perform in 
similar ways and are likely to produce similar results.[2, 4] However, because they use different 
estimation procedures, one method may produce less biased estimates than the other; for 
instance, g-estimation can be problematic if it identifies multiple possible solutions that provide 
equal counterfactual event times between treatment groups. Therefore, it is useful to run both 
RPSFTM and IPE analyses and compare the results. If the results are similar, this provides 
confidence that the results are not sensitive to the process used to identify ね. To identify which 
of the two methods fits the data better, we compared the counterfactual event times in each arm 
(i.e. counterfactual untreated event times in the LLPP arm compared to counterfactual untreated 
event times in the PPLL arm) by estimating an HR. If the method has worked successfully, the 
counterfactual HR should be equal to one. This implies that the counterfactual event times were 
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balanced between randomized arms; thus, conditions for the successful estimation of the 
treatment effect were met. 
2.2.4. Assessing the validity of the assumptions 
The patients who received treatment in the PPLL arm were a subset of patients who were 
originally randomized in CLARITY, who had not previously experienced an event, and who 
chose to enroll in CLARITY Extension. This subset could have had a greater or diminished 
potential to benefit from treatment. Therefore, we tested the sensitivity of the results to violations 
of the common treatment effect in both directions. To assess the sensitivity of the results to the 
common treatment effect assumption, we repeated the analysis with a treatment effect decrement 
of 20% for switchers. We also tested the sensitivity of the results to a potentially larger treatment 
effect in the PPLL arm by running an analysis in which the treatment effect in the PPLL arm was 
assumed to be 20% higher than in the LLPP arm. The 20% threshold, while arbitrary, was 
chosen as it is large enough to enable us to determine whether violations of the common 
treatment effect assumption were likely to be important. To assess the plausibility of the 
randomization assumption, we compared characteristics observed at the end of the CLARITY 
study between the groups of patients who did versus did not enter the extension study, and who 
had not previously experience an event of interest. If the mean characteristics of these groups are 
similar, it is likely the dropout is non-informative and will not lead to bias in the results. Further 
analyses related to potential biases associated with dropout between CLARITY and CLARITY 
Extension are published elsewhere.[17] All analyses were performed in Stata 13[18] using the 
strbee command.[16] Financial support for this study was provided entirely by a contract with 
EMD Serono, Inc. (a business of Merck KGaA, Darmstadt, Germany). The funding agreement 
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ensured the authors’ independence in designing the study, interpreting the data, writing, and 





Table 1 provides a descriptive summary of patient characteristics at the end of CLARITY for the 
subgroup of patients who had not experienced an event and did or did not enroll in the extension 
study. Note that those that received LLLL were grouped together with the LL arm patients that 
did not enter the extension study in table 1, because both groups were censored at the end of 
CLARITY in our analysis. These mean values were mostly similar between patient groups, 
however there were some statistically significant differences in terms of for EDSS, volume of T1 
Hypointense lesions and volume of T2 lesions. The results of the time to event analyses for 
3mCDP, 6mCDP, and FQR are presented in Table 2. Alongside the treatment switching adjusted 
HRs for the RPSFTM and IPE (LLPP versus PPPP), we present CLARITY ITT HRs, which 
compared the LL versus PP during CLARITY, and ITT HRs (LLPP versus PPLL), which 
compared the unadjusted arms of CLARITY plus CLARITY Extension. All treatment switching 
adjustment analyses produce numerically lower HRs than the ITT (LLPP versus PPLL) analyses.  
For 3mCDP, the RPSFTM produced a HR of 0.62 (95% CI 0.46 to 0.84) over the CLARITY 
plus CLARITY Extension period. Figure 2 presents the Kaplan Meier plot of the observed and 
counterfactual datasets associated with this RPSFTM analysis. The RPSFTM results estimated a 
HR of 0.62 (95% CI 0.44 to 0.88) for 6mCDP and a HR of 0.48 (95% CI 0.36 to 0.62) for FQR. 
The estimates of the IPE analyses are similar to the RPSFTM estimates for all analyses. The 
counterfactual HR for the RPSFTM is closer to 1, which indicated the RPSFTM performd more 
successfully than the IPE. 
Table 3 presents the results of the common treatment effect assumption sensitivity analysis. For 
each endpoint, the HR decreased by a maximum of 0.01 for a 20% increase in treatment benefit 
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for the PPLL arm and increased by a maximum of 0.01 for a 20% reduction in the treatment 
benefit. This analysis indicates the results were not highly sensitive to violations of the common 





This application of treatment switching adjustment methods to an RCT followed by an extension 
study demonstrated it is possible to apply the RPSFTM and IPE in a non-oncology context in a 
situation where all control group patients switched onto the experimental treatment. Although 
the IPE method has previously been applied in the context of an MS trial,[19] these analyses 
provide useful additional information to decision makers on longer-term treatment effect 
estimates. Treatment switching adjustment methods are relevant when patients in the trial switch 
treatments, resulting in a situation where the observed data do not represent the desired treatment 
comparison. However, while it is possible to apply adjustment methods in the setting 
investigated, because all placebo group patients who entered the extension study received 
cladribine tablets, the uncertainty around the adjustment analyses is high and these analyses 
should be considered exploratory. Yet the results of the current analysis appear to have face-
validity, given that they produce similar estimates of the treatment effect as those observed at the 
end of the initial CLARITY study period.  
The CLARITY plus CLARITY Extension study context in which we apply the RPSFTM and 
IPE is not typical, because we are not studying a single RCT, but an RCT with an extension 
study. The randomization assumption is critical for the RPSFTM and IPE and is more 
problematic in the context of an RCT followed by an extension in which not all RCT participants 
enrolled. Following CLARITY, 62% (806/1307) of patients enrolled in the extension study. This 
could potentially cause bias if the dropout was not random, i.e., if dropout is correlated with 
prognostic factors or other factors that influence the treatment effect. Assessment of the 
prognostic variables in each group indicated that the groups of patients who did and did not enter 
the extension study were mostly balanced at the end of the CLARITY (see table 1). The study 
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was not specifically powered to assess the statistical significance of differences in mean 
characteristics between these groups, hence p-values should be interpreted with caution, however 
there were some statistically significant differences in means for EDSS, volume of T1 
Hypointense lesions and volume of T2 lesions. On average, those that had not previously 
experienced an event and did not enrol into the extension had a smaller volume of T2 lesions and 
higher EDSS than those that did enrol, hence the potential impact of this on the results is unclear. 
It is important to note that unmeasured differences could also be present between the two groups 
– this cannot be ruled out and could lead to biased results.[19] A detailed exploration of the 
impact of potentially informative dropout on the results of adjustment methods applied in the 
CLARITY plus CLARITY Extension context is published elsewhere – with findings suggesting 
that informative dropout did not appear to be an important issue, in terms of measured 
characteristics.[17] Hence, even though there did appear to be some differences in characteristics 
between patients who did and did not enter the extension study, this did not appear to impact on 
estimates of the long term treatment effect.[17] 
The common treatment effect assumption required that we assume dropout between CLARITY 
and the extension study was not due to factors that influence the effectiveness of the treatment. 
Our analyses suggested adjusted HR estimates were robust to significant violations of the 
common treatment effect assumption (with a 20% increase or decrement in the treatment effect 
in switchers). Therefore, the results are unlikely to be substantially biased even if placebo group 
patients who did not enroll in the extension study had a different capacity to benefit from 
treatment to patients who did enroll. Doubt may be cast on the common treatment effect 
assumption due to the difference in time between patients in the LLPP group and patients in the 
PPLL group receiving cladribine tablets. However, given that relapsing-remitting MS is typically 
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a slowly progressive disorder, it may not be unreasonable to assume that treatment is similarly 
beneficial even if there are differences in the time of initiation. Additionally, our sensitivity 
analyses suggest this was uninfluential because the results were robust to violations of the 
common treatment effect assumption. 
The bridging interval between the end of CLARITY and the beginning of the CLARITY 
Extension introduces additional considerations. In addition to the non-informative/random 
dropout assumption, we must assume that the effect of any other treatments received during the 
bridging interval is balanced in each arm of the trial. This seems reasonable, given that only 2 
(2%) patients in the LLPP arm and 4 (2%) patients in the PPLL arm received treatment during 
the bridging interval. Ultimately, the effect of alternative treatment on outcomes was negligible. 
Furthermore, results were robust to the adjustment method used such that RPSFTM and IPE 
provided very similar adjusted HR estimates for LLPP compared to PPPP. The RPSFTM 
appeared to perform marginally better than the IPE given it produced slightly better matched 
counterfactual event times between treatment arms.  
To gauge whether the effect of cladribine tablets appeared to wane over time, we compared the 
HRs from our treatment switching adjusted analyses (LLPP versus PPPP) with the HRs from the 
CLARITY ITT analyses (LL versus PP). For time to 3mCDP, 6mCDP and FQR, the point 
estimates of the adjusted (LLPP versus PPPP) HRs were less than 10% worse than the 
CLARITY ITT (LL versus PP) HRs (0.62, 0.62, and 0.48 versus 0.60, 0.58, and 0.44, 
respectively). This might indicate a slight decrease of the treatment effect over the subsequent 
96-week placebo period of the extension study; however, therewas no clear evidence to suggest 
that the clinical treatment benefit of cladribine tablets waned during the extension.  
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It is often appropriate to apply re-censoring to the data when the RPSFTM or IPE methods are 
used to break the dependency between treatment received and censoring times. [20] In this case, 
re-censoring was not necessary because all of the patients in the PPLL arm switched treatment. 
Al l patients in the control arm that continued onto the extension had their event times adjusted, 
so there should be no dependency between the treatment received and censoring time within the 
PPLL group. We tested the sensitivity of our results to the application of re-censoring and found 
it did not make any substantial difference to the results. 
Finally, although we have undertaken rigorous analyses in an attempt to decipher as much as 
possible from the CLARITY and extension studies, additional information on longer term effects 
would be useful. For example, observational data collection could provide further evidence on 
the long-term effectiveness of cladribine tablets in real-world settings. 
In conclusion, our analysis shows the RPSFTM and IPE treatment switching adjustment methods 
can be applied in non-oncology settings, within the context of a double-blinded extension trial 
combined with an initial RCT and 100% switching from control onto experimental treatment. 
This helps to provide decision makers with evidence of longer-term treatment effectiveness in 
situations where placebo group patients in extension studies must switch onto treatment due to 
ethical reasons. A key limitation of the study, which can add uncertainty and should be 
considered alongside the results, is the potential for bias from non-random drop out at the end of 
CLARITY in terms of observed and unobserved characteristics. The comparisons of LL versus 
PP HRs and adjusted LLPP versus PPPP HRs provided no statistical evidence to suggest that the 
treatment benefit of 3.5 mg/kg (low-dose) cladribine tablets wanes over the subsequent 96 weeks 
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Table 1 Descriptive statistics of characteristics at the end of CLARITY for those that had not 
experienced an event prior to the end of CLARITY, by event and arm of initial randomization 
 
enrolled into extension and did not 
experience an event during CLARITY 
did not enroll into extension, or were re-
randomized to LLLL, and did not 
experience an event during CLARITY  
p value N Mean 
Standard 
deviation N Mean 
Standard 
deviation 
3-month confirmed disability progression PP group  
age 203 38.58 9.37 133 38.17 10.58 0.72 
sex 203 0.34 0.48 133 0.27 0.45 0.15 
EDSS at last assessment 203 2.66 1.26 133 2.94 1.53 0.08* 
T1 Gd-enhanced, volume in mm at 96 weeks 203 103.68 386.23 133 87.5 275.14 0.65 
Number of T1 Gd-enhanced lesions at 96 weeks 203 0.48 1.17 133 0.45 1.35 0.83 
T1 Hypointense lesions, volume in mm at 96 weeks 203 1462.38 2292.39 133 1366.4 2546.53 0.73 
Number of T1 Hypointense lesions at 96 weeks 203 5.61 6.07 133 5.14 5.05 0.45 
T2 lesions, volume in mm at 96 weeks 203 13380.57 12285.46 133 11087.41 9282.01 0.05** 
3-month confirmed disability progression LL group  
Age 81 37.67 10.46 284 37.31 10.23 0.79 
Sex 81 0.33 0.47 284 0.31 0.46 0.69 
EDSS at last assessment 81 2.64 1.21 284 2.60 1.23 0.78 
T1 Gd-enhanced, volume in mm at 96 weeks 81 30.19 195.12 284 11.21 70.17 0.39 
Number of T1 Gd-enhanced lesions at 96 weeks 81 0.07 0.31 284 0.06 0.34 0.79 
T1 Hypointense lesions, volume in mm at 96 weeks 81 1761.1 2917.56 284 1252.97 2055.33 0.15 
Number of T1 Hypointense lesions at 96 weeks 81 5.75 7.84 284 5.25 6.09 0.59 
T2 lesions, volume in mm at 96 weeks 81 14195.09 13444.51 284 11597.11 12746.56 0.12 
6-month confirmed disability progression PP group 
 Age 214 38.47 9.37 148 38.24 10.77 0.83 
Sex 214 0.36 0.48 148 0.30 0.46 0.31 
EDSS at last assessment 214 2.68 1.26 148 3.09 1.64 0.01*** 
T1 Gd-enhanced, volume in mm at 96 weeks 214 106.29 380.78 148 86.63 267.16 0.56 
Number of T1 Gd-enhanced lesions at 96 weeks 214 0.50 1.17 148 0.47 1.35 0.83 
T1 Hypointense lesions, volume in mm at 96 weeks 214 1444.24 2258.46 148 1465.55 2540.59 0.93 
Number of T1 Hypointense lesions at 96 weeks 214 5.53 6.02 148 5.45 5.20 0.88 
T2 lesions, volume in mm at 96 weeks 214 13471.18 12293.98 148 11922.09 11264.67 0.22 
6-month confirmed disability progression LL group  
Age 84 37.51 10.49 300 37.41 10.29 0.94 
Sex 84 0.33 0.47 300 0.31 0.46 0.73 
EDSS at last assessment 84 2.65 1.21 300 2.63 1.27 0.88 
T1 Gd-enhanced, volume in mm at 96 weeks 84 29.11 191.64 300 10.61 68.31 0.39 
Number of T1 Gd-enhanced lesions at 96 weeks 84 0.07 0.30 300 0.06 0.33 0.76 
T1 Hypointense lesions, volume in mm at 96 weeks 84 1724.51 2872.63 300 1290.33 2101.62 0.20 
Number of T1 Hypointense lesions at 96 weeks 84 5.67 7.72 300 5.37 6.28 0.75 
T2 lesions, volume in mm at 96 weeks 84 14609.87 14081.25 300 11799.52 12894.68 0.10 
First qualifying relapse PP group  
age 161 39.64 9.68 111 39.50 10.20 0.91 
sex 161 0.35 0.48 111 0.27 0.45 0.14 
EDSS at last assessment 161 2.85 1.38 111 3.19 1.70 0.09* 
T1 Gd-enhanced, volume in mm at 96 weeks 161 86.63 386.40 111 94.75 326.19 0.85 
Number of T1 Gd-enhanced lesions at 96 weeks 161 0.37 0.88 111 0.49 1.86 0.55 
T1 Hypointense lesions, volume in mm at 96 weeks 161 1459.85 2283.15 111 1375.63 2613.73 0.78 
Number of T1 Hypointense lesions at 96 weeks 161 5.72 6.24 111 5.19 4.75 0.43 
T2 lesions, volume in mm at 96 weeks 161 13231.12 12430.89 111 11081.81 9669.58 0.11 
First qualifying relapse LL group  
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age 82 38.48 9.98 266 37.95 10.25 0.68 
sex 82 0.32 0.47 266 0.30 0.46 0.78 
EDSS at last assessment 82 2.95 1.45 266 2.68 1.32 0.13 
T1 Gd-enhanced, volume in mm at 96 weeks 82 29.73 193.90 266 9.86 67.53 0.36 
Number of T1 Gd-enhanced lesions at 96 weeks 82 0.07 0.31 266 0.06 0.33 0.67 
T1 Hypointense lesions, volume in mm at 96 weeks 82 2138.57 3145.42 266 1359.83 2206.04 0.04** 
Number of T1 Hypointense lesions at 96 weeks 82 6.67 8.03 266 5.64 6.68 0.29 
T2 lesions, volume in mm at 96 weeks 82 15829.02 13924.13 266 12024.73 13332.88 0.03** 
CLARITY: Cladribine Tablets Treating Multiple Sclerosis Orally (trial), EDSS: Expanded Disability Status Scale, Gd:gadolinium, LL: low-dose 
cladribine in CLARITY, LLPP low-dose cladribine in CLARITY followed by placebo in CLARITY Extension, N: Number of observations, PP: 
















CF HR Test: Counterfactual Hazard Ratio Test, CLARITY: Cladribine Tablets Treating Multiple Sclerosis Orally (trial), CI: confidence interval, 
HR; hazard ratio, IPE: Iterative Parameter Estimation, ITT: Intention to treat, LL: low-dose cladribine in CLARITY, LLLL: low-dose cladribine 
in CLARITY followed by low-dose in CLARITY Extension; LLPP low-dose cladribine in CLARITY followed by placebo in CLARITY 
Extension, PP: placebo in CLARITY, PPLL: placebo in CLARITY followed by low-dose cladribine in CLARITY Extension, PPPP: placebo in 















Time to 3-month progression 
ITT (LLPP vs PPLL) 0.67 0.52 0.87 - 
CLARITY ITT (LL vs PP) 0.60 0.41 0.87 - 
RPSFTM (LLPP vs PPPP) 0.62 0.46 0.84 1.00 
IPE (LLPP vs PPPP) 0.62 0.45 0.83 0.94 
Time to 6-month progression 
ITT (LLPP vs PPLL) 0.67 0.50 0.90 - 
CLARITY ITT (LL vs PP) 0.58 0.40 0.83 - 
RPSFTM (LLPP vs PPPP) 0.62 0.44 0.88 1.01 
IPE (LLPP vs PPPP) 0.62 0.43 0.87 0.98 
Time to First qualifying relapse 
ITT (LLPP vs PPLL) 0.53 0.43 0.67 - 
CLARITY ITT (LL vs PP) 0.44 0.34 0.58 - 
RPSFTM (LLPP vs PPPP)  0.48 0.36 0.62 1.00 
IPE (LLPP vs PPPP) 0.48 0.37 0.62 0.95 
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         CI: confidence interval, HR: hazard ratio, PPLL: placebo in CLARITY followed by low-dose cladribine in CLARITY 










Time to 3-month progression 
treatment benefit for PPLL is reduced by 20% 0.63 0.46 0.85 
treatment benefit for PPLL is increased by 20% 0.61 0.44 0.84 
Time to 6-month progression 
treatment benefit for PPLL is reduced by 20% 0.63 0.45 0.88 
treatment benefit for PPLL is increased by 20% 0.61 0.42 0.87 
Time to first qualifying relapse 
treatment benefit for PPLL is reduced by 20% 0.48 0.37 0.63 




Fig 1 CLARITY and CLARITY Extension arms used for analysis 
Fig 2 Kaplan Meier plot for 3-month progression 
 
